Regional excess mortality during the 2020 COVID-19 pandemic: a study of five European countries

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

G.K. is supported by an MRC Skills Development Fellowship [MR/T025352/1]. M.B. is supported by a National Institutes of Health, grant number [R01HD092580-01A1]. Infrastructure support for this research was provided by the National Institute for Health Research Imperial Biomedical Research Centre (BRC). The work was partly supported by the MRC Centre for Environment and Health, which is funded by the Medical Research Council (MR/S019669/1, 2019-2024). V. Gomez-Rubio is supported by grant SBPLY/17/180501/000491, funded by Consejeria de Educacion, Cultura y Deportes (JCCM, Spain) and FEDER, and grant PID2019-106341GB-I00, funded by Ministerio de Ciencia e Innovacion (Spain). M.E. and J.R. are supported by by the Swiss National Science Foundation (grant 189498). The study uses Small Area Health Statistics (SAHSU) data, obtained from the Office for National Statistics. The work of the UK SAHSU Unit is overseen by Public Health England (PHE) and funded by PHE as part of the MRC-PHE Centre for Environment and Health also supported by the UK Medical Research Council, Grant number: MR/L01341X/1), and the National Institute for Health Research (NIHR) through its Health Protection Units (HPRUs) at Imperial College London in Environmental Exposures and Health and in Chemical and Radiation Threats and Hazards, and through Health Data Research UK (HDR UK). This paper does not necessarily reflect the views of Public Health England, the National Institute for Health Research or the Department of Health and Social Care.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The analyses for England were covered by national research ethics approval from the London-South East Research Ethics Committee (Reference 17/LO/0846). Data access was covered by the Health Research Authority Confidentiality Advisory Group under section 251 of the National Health Service Act 2006 and the Health Service (Control of Patient Information) Regulations 2002 (Reference 20/CAG/0028). Data access for Greece was approved by the 28th Statistical Privacy Committee and the relevant letter of the president of the Hellenic Statistical Authority (ΓΠ-498/23-12-2020) in accordance with section 5.3 of the Minutes of the Statistical Privacy Committee. The study is about secondary, aggregate anonymised data so no additional ethical permission is required.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes